| [1] | BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834 |
| [2] | YAMADA Y. Present status and perspective of chemotherapy for patients with unresectable advanced or metastatic gastric cancer in Japan[J]. Glob Health Med, 2020, 2(3):156-163. doi: 10.35772/ghm.2019.01025 |
| [3] | AJANI J A, D’AMICO T A, BENTREM D J, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2):167-192. doi: 10.6004/jnccn.2022.0008 |
| [4] | 辛文秀, 黄萍, 卢晓阳, 等. 紫杉醇制剂超敏反应预处理指导意见[J]. 中国现代应用药学, 2019, 36(8):1023-1027. |
| [5] | 国家癌症中心, 中国药师协会肿瘤专科药师分会. 紫杉类抗肿瘤药物药学服务中国专家共识[J]. 中国医院用药评价与分析, 2022, 22(12):1409-1427. |
| [6] | MARKMAN M, KENNEDY A, WEBSTER K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland clinic cancer center[J]. J Clin Oncol, 2000, 18(1):102-105. doi: 10.1200/JCO.2000.18.1.102 |
| [7] | LANSINGER O M, BIEDERMANN S, HE Z, et al. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions. J Clin Oncol. 2021;39(32): 3583-3590. |
| [8] | CHEN F C, WANG L H, ZHENG X Y, et al. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions. Oncotarget. 2017;8(12): 19236-19243. |
| [9] | O'CATHAIL S M, SHABOODIEN R, MAHMOUD S, et al. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies. Int J Gynecol Cancer. 2013;23(7): 1318-25. |
| [10] | ALMUHIZI F, DE LAS VECILLAS SANCHEZ L, GILBERT L, et al. Premedication protocols to prevent hypersensitivity reactions to chemotherapy: a literature review[J]. Clin Rev Allergy Immunol, 2022, 62(3):534-547. doi: 10.1007/s12016-022-08932-2 |
| [11] | BEAUCAGE-CHARRON J, GAUDET L, LAMOTHE S, et al. A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study[J]. Support Care Cancer, 2022, 30(4):3389-3399. doi: 10.1007/s00520-021-06734-4 |
| [12] | MALMBERG R, VAN DOORN L, COX J M, et al. Effect of switching the histamine-1 receptor antagonist clemastine to cetirizine in paclitaxel premedication regimens: the H1-switch study[J]. JCO Oncol Pract, 2024, 20(9):1243-1251. doi: 10.1200/OP.24.00110 |
| [13] | COX J M, VAN DOORN L, MALMBERG R, et al. The added value of H2 antagonists in premedication regimens during paclitaxel treatment[J]. Br J Cancer, 2021, 124(10):1647-1652. doi: 10.1038/s41416-021-01313-0 |
| [14] | TSANG C, ROBINSON J, WHEATLEY-PRICE P F, et al. The utility of H2 receptor antagonists in preventing infusion-related reactions to paclitaxel chemotherapy[J]. Cancer, 2023, 129(23):3815-3819. doi: 10.1002/cncr.35006 |
| [15] | PÉREZ O M, BENAVIDES J M, FERNANDEZ T G, et al. Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study[J]. Expert Rev Clin Pharmacol, 2023, 16(9):877-883. doi: 10.1080/17512433.2023.2238596 |
| [16] | FOREMAN E, POLWART C, WALKER A, et al. Histamine-2(H2)antagonists can be safely removed from standard paclitaxel premedication regimens[J]. Br J Clin Pharmacol, 2022, 88(9):4191-4198. doi: 10.1111/bcp.15363 |
| [17] | GELDERBLOM H, ZWAVELING J. No need for H2-antagonists in premedication regimens for paclitaxel infusions: less is more[J]. Br J Cancer, 2021, 124(10):1613-1614. doi: 10.1038/s41416-021-01316-x |
| [18] | STROBBE G, GABORIAU L, ABELÉ M, et al. Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France(PACLIREACT Study)[J]. Eur J Clin Pharmacol, 2023, 79(9):1229-1238. doi: 10.1007/s00228-023-03536-x |
| [19] | MARTÍ-GARRIDO J, VÁZQUEZ-REVUELTA P, LLEONART-BELLFILL R, et al. Pilot experience using drug provocation testing for the study of hypersensitivity to chemotherapy and biological agents[J]. J Investig Allergol Clin Immunol, 2021, 31(2):166-168. doi: 10.18176/jiaci.0552 |
| [20] | GONZÁLEZ R V V, DÍAZ S N G, CRUZ R A C, et al. Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization[J]. J Oncol Pharm Pract, 2022, 28(3):598-604. doi: 10.1177/10781552211008503 |